Cargando…

Computerized tumor-infiltrating lymphocytes density score predicts survival of patients with resectable lung adenocarcinoma

A high abundance of tumor-infiltrating lymphocytes (TILs) has a positive impact on the prognosis of patients with lung adenocarcinoma (LUAD). We aimed to develop and validate an artificial intelligence-driven pathological scoring system for assessing TILs on H&E-stained whole-slide images of LUA...

Descripción completa

Detalles Bibliográficos
Autores principales: Pan, Xipeng, Lin, Huan, Han, Chu, Feng, Zhengyun, Wang, Yumeng, Lin, Jiatai, Qiu, Bingjiang, Yan, Lixu, Li, Bingbing, Xu, Zeyan, Wang, Zhizhen, Zhao, Ke, Liu, Zhenbing, Liang, Changhong, Chen, Xin, Li, Zhenhui, Cui, Yanfen, Lu, Cheng, Liu, Zaiyi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9730047/
https://www.ncbi.nlm.nih.gov/pubmed/36505920
http://dx.doi.org/10.1016/j.isci.2022.105605
Descripción
Sumario:A high abundance of tumor-infiltrating lymphocytes (TILs) has a positive impact on the prognosis of patients with lung adenocarcinoma (LUAD). We aimed to develop and validate an artificial intelligence-driven pathological scoring system for assessing TILs on H&E-stained whole-slide images of LUAD. Deep learning-based methods were applied to calculate the densities of lymphocytes in cancer epithelium (DLCE) and cancer stroma (DLCS), and a risk score (WELL score) was built through linear weighting of DLCE and DLCS. Association between WELL score and patient outcome was explored in 793 patients with stage I-III LUAD in four cohorts. WELL score was an independent prognostic factor for overall survival and disease-free survival in the discovery cohort and validation cohorts. The prognostic prediction model-integrated WELL score demonstrated better discrimination performance than the clinicopathologic model in the four cohorts. This artificial intelligence-based workflow and scoring system could promote risk stratification for patients with resectable LUAD.